Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20744358 | 0.86 | — | — | |
| SCHEMBL20744336 | 0.86 | — | — | |
| SCHEMBL20744288 | 0.83 | HTR1A (0.53) | — | |
| SCHEMBL20744365 | 0.82 | EPHX2 (0.47) | EPHX2 | |
| SCHEMBL20744366 | 0.81 | NAMPT (0.48) | — | |
| SCHEMBL20753907 | 0.77 | — | — | |
| SCHEMBL20744360 | 0.76 | EPHX2 (0.48) | EPHX2 | |
| SCHEMBL30305368 | 0.76 | EPHX2 (0.51) | EPHX2 | |
| SCHEMBL20744371 | 0.76 | EPHX2 (0.51) | EPHX2 | |
| SCHEMBL30305346 | 0.76 | EPHX2 (0.48) | EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240307385-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-09-19 | — | — | US | claimed |
| CN-111225910-B | Novel compounds | 葛兰素史密斯克莱知识产权发展有限公司 | 2023-03-24 | — | — | CN | claimed |
| EP-3668853-B1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2021-09-29 | — | — | EP | claimed |
| US-20200253967-A1 | NOVEL COMPOUNDS | BioVersys AG (CH) | 2020-08-13 | — | — | US | claimed |
| EP-3668853-A1 | NOVEL COMPOUNDS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2020-06-24 | — | — | EP | claimed |
| CN-111225910-A | Novel compounds | 葛兰素史密斯克莱知识产权发展有限公司 | 2020-06-02 | — | — | CN | claimed |
| WO-2019034701-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-02-21 | — | — | WO | claimed |
| US-20240307385-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-09-19 | — | — | US | disclosed |
| US-11969423-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-04-30 | — | — | US | disclosed |
| CN-111225910-B | Novel compounds | 葛兰素史密斯克莱知识产权发展有限公司 | 2023-03-24 | — | — | CN | disclosed |
| EP-3668853-B1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2021-09-29 | — | — | EP | disclosed |
| EP-3668853-B1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2021-09-29 | — | — | EP | disclosed |
| US-20200253967-A1 | NOVEL COMPOUNDS | BioVersys AG (CH) | 2020-08-13 | — | — | US | disclosed |
| US-20200253967-A1 | NOVEL COMPOUNDS | BioVersys AG (CH) | 2020-08-13 | — | — | US | disclosed |
| EP-3668853-A1 | NOVEL COMPOUNDS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2020-06-24 | — | — | EP | disclosed |
| CN-111225910-A | Novel compounds | 葛兰素史密斯克莱知识产权发展有限公司 | 2020-06-02 | — | — | CN | disclosed |
| WO-2019034701-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240307385-A1 | NOVEL COMPOUNDS | FNTB, SDHA, FDPS | EPHX2 2721/4885 |
| US-20200253967-A1 | NOVEL COMPOUNDS | FNTB, SDHA, FDPS | EPHX2 2721/4885 |
| US-11969423-B2 | Compounds | SDHA, SDHB, FDPS | EPHX2 1674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.